Compare with Novartis - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ALKEM LABORATORIES vs NOVARTIS - Comparison Results

NOVARTIS 
   Change

Novartis is a 76% subsidiary of Novartis AG - Switzerland and has a countrywide presence in the healthcare business. While pharmaceuticals contributes 70% to total revenues (FY10), generics (6%), consumer healthcare i.e. OTC (14%) and animal health (... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ALKEM LABORATORIES NOVARTIS ALKEM LABORATORIES/
NOVARTIS
 
P/E (TTM) x 23.0 2,064.8 1.1% View Chart
P/BV x 5.6 27.4 20.2% View Chart
Dividend Yield % 0.9 1.6 54.2%  

Financials

 ALKEM LABORATORIES   NOVARTIS
EQUITY SHARE DATA
    ALKEM LABORATORIES
Mar-20
NOVARTIS
Mar-19
ALKEM LABORATORIES/
NOVARTIS
5-Yr Chart
Click to enlarge
High Rs2,720980 277.6%   
Low Rs1,660600 276.6%   
Sales per share (Unadj.) Rs697.9198.7 351.2%  
Earnings per share (Unadj.) Rs96.121.0 458.4%  
Cash flow per share (Unadj.) Rs117.322.3 526.9%  
Dividends per share (Unadj.) Rs25.0010.00 250.0%  
Dividend yield (eoy) %1.11.3 90.2%  
Book value per share (Unadj.) Rs515.2307.5 167.6%  
Shares outstanding (eoy) m119.5724.69 484.3%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x3.14.0 78.9%   
Avg P/E ratio x22.837.7 60.5%  
P/CF ratio (eoy) x18.735.5 52.6%  
Price / Book Value ratio x4.32.6 165.4%  
Dividend payout %26.047.7 54.5%   
Avg Mkt Cap Rs m261,87919,508 1,342.4%   
No. of employees `00014.30.6 2,466.6%   
Total wages/salary Rs m15,0551,171 1,285.5%   
Avg. sales/employee Rs Th5,822.68,445.4 68.9%   
Avg. wages/employee Rs Th1,050.52,015.7 52.1%   
Avg. net profit/employee Rs Th802.0891.0 90.0%   
INCOME DATA
Net Sales Rs m83,4444,907 1,700.6%  
Other income Rs m1,042783 133.2%   
Total revenues Rs m84,4865,689 1,485.0%   
Gross profit Rs m14,734123 11,998.3%  
Depreciation Rs m2,52832 7,948.4%   
Interest Rs m65116 4,091.8%   
Profit before tax Rs m12,598858 1,468.8%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1,105340 324.9%   
Profit after tax Rs m11,493518 2,220.0%  
Gross profit margin %17.72.5 705.5%  
Effective tax rate %8.839.6 22.1%   
Net profit margin %13.810.6 130.5%  
BALANCE SHEET DATA
Current assets Rs m54,9608,055 682.4%   
Current liabilities Rs m32,4331,850 1,753.0%   
Net working cap to sales %27.0126.4 21.4%  
Current ratio x1.74.4 38.9%  
Inventory Days Days8045 176.8%  
Debtors Days Days7234 212.7%  
Net fixed assets Rs m32,710150 21,835.6%   
Share capital Rs m239123 193.8%   
"Free" reserves Rs m61,3687,469 821.7%   
Net worth Rs m61,6077,592 811.5%   
Long term debt Rs m1,5920-   
Total assets Rs m99,4339,824 1,012.1%  
Interest coverage x20.454.9 37.1%   
Debt to equity ratio x00-  
Sales to assets ratio x0.80.5 168.0%   
Return on assets %12.25.4 224.9%  
Return on equity %18.76.8 273.6%  
Return on capital %21.011.5 182.2%  
Exports to sales %19.10-   
Imports to sales %3.00-   
Exports (fob) Rs m15,917NA-   
Imports (cif) Rs m2,483NA-   
Fx inflow Rs m16,06158 27,884.0%   
Fx outflow Rs m2,4831,326 187.2%   
Net fx Rs m13,578-1,269 -1,070.3%   
CASH FLOW
From Operations Rs m5,851-1,943 -301.2%  
From Investments Rs m-7,4142,742 -270.3%  
From Financial Activity Rs m792-298 -265.4%  
Net Cashflow Rs m-731501 -145.8%  

Share Holding

Indian Promoters % 66.9 0.0 -  
Foreign collaborators % 0.0 75.0 -  
Indian inst/Mut Fund % 33.1 2.0 1,655.0%  
FIIs % 0.0 1.6 -  
ADR/GDR % 0.0 0.0 -  
Free float % 0.0 21.5 -  
Shareholders   68,381 41,647 164.2%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ALKEM LABORATORIES With:   UNICHEM LAB  VENUS REMEDIES  CIPLA  GLENMARK PHARMA  AUROBINDO PHARMA  

Compare ALKEM LABORATORIES With:   ACTAVIS (US)  MYLAN (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Indian Share Markets Open Higher; JSW Steel & Tata Steel Top Gainers(09:30 am)

Asian share markets edged higher today as investors shrugged off concerns that stocks may have rallied too far too fast in the past year.

Related Views on News

NOVARTIS Announces Quarterly Results (3QFY20); Net Profit Down 39.9% (Quarterly Result Update)

Feb 17, 2020 | Updated on Feb 17, 2020

For the quarter ended December 2019, NOVARTIS has posted a net profit of Rs 77 m (down 39.9% YoY). Sales on the other hand came in at Rs 1 bn (down 13.4% YoY). Read on for a complete analysis of NOVARTIS's quarterly results.

NOVARTIS Announces Quarterly Results (1QFY20); Net Profit Down 92.1% (Quarterly Result Update)

Aug 13, 2019 | Updated on Aug 13, 2019

For the quarter ended June 2019, NOVARTIS has posted a net profit of Rs 8 m (down 92.1% YoY). Sales on the other hand came in at Rs 1 bn (down 20.8% YoY). Read on for a complete analysis of NOVARTIS's quarterly results.

NOVARTIS Announces Quarterly Results (4QFY19); Net Profit Down 26.2% (Quarterly Result Update)

May 30, 2019 | Updated on May 30, 2019

For the quarter ended March 2019, NOVARTIS has posted a net profit of Rs 195 m (down 26.2% YoY). Sales on the other hand came in at Rs 1 bn (down 11.9% YoY). Read on for a complete analysis of NOVARTIS's quarterly results.

NOVARTIS Announces Quarterly Results (3QFY20); Net Profit Down 39.9% (Quarterly Result Update)

Feb 17, 2020 | Updated on Feb 17, 2020

For the quarter ended December 2019, NOVARTIS has posted a net profit of Rs 77 m (down 39.9% YoY). Sales on the other hand came in at Rs 1 bn (down 13.4% YoY). Read on for a complete analysis of NOVARTIS's quarterly results.

NOVARTIS Announces Quarterly Results (1QFY20); Net Profit Down 92.1% (Quarterly Result Update)

Aug 13, 2019 | Updated on Aug 13, 2019

For the quarter ended June 2019, NOVARTIS has posted a net profit of Rs 8 m (down 92.1% YoY). Sales on the other hand came in at Rs 1 bn (down 20.8% YoY). Read on for a complete analysis of NOVARTIS's quarterly results.

More Views on News

Most Popular

It's the Beginning of a New Bull Phase in Smallcaps(Profit Hunter)

Feb 24, 2021

Last time the smallcap index crossed 19k a big correction followed. Here's what makes it different this time.

Make Rs 5,000 Per Day Trading the Market(Fast Profits Daily)

Feb 25, 2021

In this video, I'll show you how to get started on the path to daily trading profits.

I Believe the Investment of the Year Will Be...

Feb 19, 2021

In this episode, ace trader Brijesh Bhatia talks to us about the best investments of 2021, his profitable trading system, and much more.

The Hidden Tesla in My Great Indian Wealth Project(Profit Hunter)

Feb 23, 2021

An Indian company founded three decades ago in a garage caught my attention...

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

ALKEM LABORATORIES SHARE PRICE


Mar 3, 2021 11:38 AM

TRACK ALKEM LABORATORIES

  • Track your investment in ALKEM LABORATORIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ALKEM LABORATORIES

ALKEM LABORATORIES - UNICHEM LAB COMPARISON

COMPARE ALKEM LABORATORIES WITH

MARKET STATS